Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen
Conclusions: A primary personalized cardioprotection strategy decreases the number of cardiac deaths and may potentially prolong overall survival in NHL patients with increased risk of anthracycline cardiotoxicity.Chemotherapy 2018;63:238 –245
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
More News: Bisoprolol | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Heart | Heart Failure | History of Medicine | Lymphoma | Non-Hodgkin's Lymphoma | Study